Andrew Huberman joins TBPN: retreutide, peptide legality, cannabis psychosis risk, and Olympic athlete biohacking

Summary

Andrew Huberman discusses consumer health products, performance enhancement in elite athletes, peptide safety and legality, and emerging risks around cannabis use.

Matinas Yerba Mate and caffeine timing

Huberman co-owns Matinas, a zero-sugar cold brew yerba mate brand stocked in Whole Foods, Costco Canada, Sprouts Markets, and Amazon. He positions it as a cleaner caffeine alternative to conventional energy drinks, high in antioxidants and a mild appetite suppressant, with no additives like alpha-GPC or taurine. The product comes in five flavors and uses BPA-, BPS-, and PFAS-free cans. Huberman consumes four to six cans daily due to high caffeine tolerance; most users need one or two. He cuts caffeine by 2 p.m. to protect sleep, though he front-loads it on workout days to enhance performance. Caffeine is heavily regulated in sport because of its ergogenic effect, but it carries risk for people with anxiety.

Olympic athlete biohacking and vasodilators

Elite athletes are using vasodilators like tadalafil (Cialis) and sildenafil (Viagra) to lower blood pressure, reduce pre-competition anxiety, and improve muscle perfusion. Huberman cites Stanford's Mike Eisenberg, head of male sexual health, who recommends that most males aged 40 and older take 2.5 to 5 milligrams of tadalafil daily for preventative cardiovascular and prostate health, not just erectile function. Athletes exploit the fact that many vasodilators remain off banned lists. Huberman notes a historical pattern: drugs like bromocriptine and apomorphine, once used to enhance dopamine and acetylcholine for sprint performance, are now banned. Shooting sports athletes favor blood-pressure-lowering compounds. He mentions anecdotal reports of skiers injecting their genitals to increase bulge size for air resistance.

Peptide legality and sourcing risks

Peptides are short amino acid chains covering everything from insulin to synthetic growth hormone secretagogues like tesamorelin and ipramerelin, many of which are FDA-approved but obtained through compounding pharmacies or gray and black markets rather than pharmaceutical companies. Huberman strongly discourages buying peptides labeled "for research purposes only" because they often contain lipopolysaccharide (LPS) contaminants in the remaining 1% purity. Daily injections over weeks can trigger autoimmune effects. He distinguishes between FDA-approved peptides, which are legal, and gray-market research chemicals, which pose contamination and legal risk.

BPC-157 and pinealine

BPC-157, a synthetic gut peptide, is widely claimed to accelerate wound healing, increase vascular and nerve growth, and regrow cartilage. Animal studies support the mechanism, and the lethal dose is extremely high, but controlled human trials do not exist. Huberman notes the logical backbone is sound and adoption is widespread, but the absence of a control arm makes efficacy claims largely anecdotal. Pinealine purportedly doubled his REM sleep to nearly three hours per night and may enhance pineal gland health, though he stopped using it after developing AGZ, a sleep formula he helped design, which delivers 2.5 hours of REM and abundant deep sleep.

Retreutide: the trillion-dollar peptide game

Eli Lilly owns a patent on retreutide, a GLP-1/GLP-3 triple agonist that caused one-third body weight loss in six months during phase three trials, with some muscle sparing. The bodybuilding community adopted it first, then fitness trainers, then high-profile clients and Hollywood figures, who publicly credit diet and training while privately using growth hormone and retreutide. People are already injecting black-market retreutide at roughly one-third the clinical trial dose with reported excellent fat-loss results. Huberman receives approximately 100 questions weekly about retreutide on his personal phone. Lilly stands to capture a trillion-dollar market, creating pressure to tighten peptide regulations. Lawmakers are considering making peptide purchases illegal, even through compounding pharmacies, to protect Lilly's patent exclusivity. Huberman has never used retreutide himself but knows people who report phenomenal results at fractional doses.

Secondary effects and impulse control

Beyond weight loss, GLP agonists reduce alcohol appetite and impulsivity. Receptors for these molecules populate the brain and body. The hypothalamus, which governs impulsivity and anxiety, is a key site. Clinical trials of GLP agonists have examined alcohol use disorder and binge eating disorder. Huberman emphasizes that adults and fully-formed bodies occupy a different risk landscape than adolescents and young adults.

Age-dependent endocrine risk

Huberman is "very concerned" about young people, especially women, considering testosterone replacement therapy. He microdosed testosterone at age 45, now 50, while maintaining fertility via HCG, but says he would never recommend this to anyone in their twenties or thirties without serious clinical cause. Augmenting growth hormone in teens and twenties can disrupt the hypothalamic-pituitary-gonadal axis, cause infertility, and trigger depression upon cessation. The "looks maxing" phenomenon of pursuing cosmetic muscularity via peptides and hormones is, in his view, "really, really dangerous and foolish" in people under 40. Exogenous hormones can alter developmental trajectories, leaving people looking older in their forties and fifties. Growth hormone increases vitality but accelerates aging; bigger dogs die sooner than smaller ones due to higher growth hormone and IGF-1 dosing. Testosterone offers energy, exercise recovery, and libido but demands cost-benefit analysis. Muscle and fat loss may extend lifespan if paired with training, but cosmetic chasing—"an angle jawline, abs"—via social media pressure warrants psychological investment, not peptides.

Puberty is protracted. Huberman did not shave until age 20, and his head and face continued changing. Parents often ask about growth hormone for shorter children, conflating medical use with enhancement. A new non-amphetamine ADHD drug, Sunosi, shows promise for excessive daytime sleepiness and may offer an alternative to Adderall and Vyvanse. He recommends Dr. John Kruse's YouTube channel for evidence-based ADHD coverage.

Cannabis psychosis risk and THC concentration

Huberman holds a personal stance favoring legalization with regulation. He hosted two guests and produced a solo episode on cannabis, stating that young males with a family history of schizophrenia or bipolar disorder face high risk of cannabis-induced psychosis, some of which does not reverse. Traditional media outlets accused him of spreading misinformation, but those same outlets now report that cannabis can cause psychosis. A Canadian researcher guest attributed psychosis risk to excessive THC ingestion, noting that inhalation produces a more moderate high than edibles and carries lower psychotic risk. Keith Humphrey, a Stanford clinician and addiction expert, disagreed, saying he observes psychosis risk even among inhalers. THC concentration, dosing frequency, and genetic predisposition all matter. The core risk is discovering a latent psychotic predisposition by using high-THC cannabis, making users "part of the experiment." Kratom presents a similar pattern. Some people credit it with opioid cessation, and activist groups promote it, yet underlying risks vary by individual.